OTCMKTS:OPHLY Ono Pharmaceutical (OPHLY) Stock Price, News & Analysis $4.73 -0.02 (-0.42%) As of 03:18 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About Ono Pharmaceutical Stock (OTCMKTS:OPHLY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ono Pharmaceutical alerts:Sign Up Key Stats Today's Range$4.73▼$4.7550-Day Range$4.75▼$5.4052-Week Range$3.71▼$5.75Volume19,217 shsAverage Volume35,947 shsMarket CapitalizationN/AP/E Ratio1.04Dividend Yield350.04%Price TargetN/AConsensus RatingN/A Company Overview Ono Pharmaceutical Co., Ltd. is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its principal focus areas include oncology, immunology, neurology and other specialty diseases, with an emphasis on innovative treatments for conditions with significant unmet medical needs. The company is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer. Ono also markets other prescription medicines and has developed or commercialized products through research collaborations and licensing arrangements with pharmaceutical companies in Japan and overseas. Ono Pharmaceutical traces its origins to 1717, when it began as a traditional medicine business in Osaka, Japan. It has since evolved into a research-based global pharmaceutical company, serving patients primarily in Japan and, through partnerships and international commercialization agreements, markets around the world. The company is headquartered in Osaka and is led by President and Chief Executive Officer Gyo Sagara.AI Generated. May Contain Errors. Read More Receive OPHLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OPHLY Stock News HeadlinesOno Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological DiseasesSeptember 1, 2026 | businesswire.comOno Pharmaceutical Co. - depositary receipt (OPHLY) price target decreased by 13.89% to 2.21February 24, 2026 | msn.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.October 7 at 1:00 AM | Reagan Gold Group (Ad)Pfizer says cancer therapy Braftovi improved survival in late-stage trialFebruary 17, 2026 | msn.comOno Pharmaceutical Co. - Depositary receipt (OPHLY) price target increased by 28.77% to 2.56February 4, 2026 | msn.comOno Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference PresentationJanuary 15, 2026 | finance.yahoo.comOno Pharmaceutical Co., - depositary receipt (OPHLY) price target increased by 30.66% to 1.99December 22, 2025 | msn.comOno Pharmaceutical Co., - Depositary Receipt (OPHLY) Price Target Decreased by 17.63% to 1.52November 17, 2025 | msn.comSee More Headlines OPHLY Stock Analysis - Frequently Asked Questions How have OPHLY shares performed this year? Ono Pharmaceutical's stock was trading at $4.55 at the beginning of the year. Since then, OPHLY stock has increased by 4.0% and is now trading at $4.73. How do I buy shares of Ono Pharmaceutical? Shares of OPHLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/07/2026Next Earnings (Estimated)10/29/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:OPHLY CIK940821 Webwww.ono-pharma.com Phone(166) 263-5670FaxN/AEmployees4,206Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio1.04 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:OPHLY) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ono Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ono Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
